AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22122605 — intervention group
Group type: COMPARATOR
Intervention: Control group without treatment
Number of subjects: 0
Study 19917571 — intervention group
Group type: EXPERIMENTAL
Intervention: PI-88 in combination with docetaxel (75 mg/m2 every three weeks)
Number of subjects: 56
Study 18381807 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-drained group
Number of subjects: 116
Study 18381807 — intervention group
Group type: COMPARATOR
Intervention: Drained group
Number of subjects: 116
Study 16231269 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial interference with Escherichia coli 83972
Number of subjects: 27
Study 16231269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 12646667 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 1088
Study 12646667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1088
Study 10229064 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (6 mg/day)
Number of subjects: 18
Study 10229064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8912562 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcitriol (0.5 to 2 micrograms daily)
Number of subjects: 16
Study 8912562 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB phototherapy
Number of subjects: 16
Study 8912562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1819620 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g i.v. of imipenem‐cilastatin at induction of anesthesia
Number of subjects: 61
Study 1819620 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime (1.5 g i.v.) plus metronidazole (0.5 g i.v.) at the time of anesthesia and two other administrations of the combined antibiotics (cefuroxime 0.75 g plus metronidazole 0.5 g i.v.) every 8 hours
Number of subjects: 61
Study 6698566 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.8 g/kg)
Number of subjects: 8
Study 6698566 — intervention group
Group type: COMPARATOR
Intervention: Meptazinol (200 mg 3 hourly for 4 doses)
Number of subjects: 8
Study 6698566 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol (200 mg 3 hourly for 4 doses) + Ethanol (0.8 g/kg)
Number of subjects: 8
Study 6698566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30961456 — intervention group
Group type: EXPERIMENTAL
Intervention: Stanford orientation
Number of subjects: 0
Study 30961456 — intervention group
Group type: COMPARATOR
Intervention: Control orientation
Number of subjects: 0
Study 29526852 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Mechanical Peripheral Stimulation (AMPS), n = 16
Number of subjects: 33
Study 29526852 — intervention group
Group type: COMPARATOR
Intervention: AMPS SHAM, n = 17
Number of subjects: 33
Study 26597401 — intervention group
Group type: EXPERIMENTAL
Intervention: SPRM/CDSS intervention
Number of subjects: 361
Study 26597401 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmaceutical care (control)
Number of subjects: 361
Study 24428351 — intervention group
Group type: EXPERIMENTAL
Intervention: HeRO Graft
Number of subjects: 143
Study 24428351 — intervention group
Group type: COMPARATOR
Intervention: Conventional AV graft
Number of subjects: 143
Study 23672904 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-extended, extra-articular, parapatellar approach intramedullary nail
Number of subjects: 18
Study 23672904 — intervention group
Group type: COMPARATOR
Intervention: Control group (uninjured patients)
Number of subjects: 18
Study 23672904 — intervention group
Group type: EXPERIMENTAL
Intervention: Fracture group
Number of subjects: 18
Study 21045674 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (0.1%)
Number of subjects: 67
Study 21045674 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose (0.5%)
Number of subjects: 67
Study 21045674 — intervention group
Group type: COMPARATOR
Intervention: Both SH and CMC
Number of subjects: 67
Study 18787526 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored weight loss intervention
Number of subjects: 144
Study 18787526 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 144
Study 16525856 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI treatment
Number of subjects: 32
Study 14602694 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 0.2 mg/kg
Number of subjects: 111
Study 14602694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 14602694 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (after 2 hours)
Number of subjects: 111
Study 14602694 — intervention group
Group type: EXPERIMENTAL
Intervention: Failed ductal constriction
Number of subjects: 111
Study 14602694 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial SVC flow
Number of subjects: 111
Study 11024412 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser photocoagulation
Number of subjects: 70
Study 11024412 — intervention group
Group type: EXPERIMENTAL
Intervention: Submacular surgery
Number of subjects: 70
Study 8758193 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose chemotherapy
Number of subjects: 0
Study 8758193 — intervention group
Group type: COMPARATOR
Intervention: Best conventional therapy
Number of subjects: 0
Study 1514713 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium meglumine ioxaglate
Number of subjects: 80
Study 1514713 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 80
Study 6581492 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium plus acute haloperidol
Number of subjects: 9
Study 6581492 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium plus chronic haloperidol
Number of subjects: 9
Study 6581492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 6581492 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 9
Study 31442202 — intervention group
Group type: EXPERIMENTAL
Intervention: Attended stimuli
Number of subjects: 0
Study 31442202 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 30092411 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy (amlodipine 10 mg od; lisinopril 20 mg od; chlorthalidone 25 mg od)
Number of subjects: 1320
Study 30092411 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (amlodipine 5 mg od and lisinopril 20 mg od; amlodipine 5 mg od and chlorthalidone 25 mg od; lisinopril 20 mg od and chlorthalidone 25 mg od; amiloride 10 mg od and chlorthalidone 25 mg od)
Number of subjects: 1320
Study 27329829 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap with connective tissue graft (CAF + CTG)
Number of subjects: 32
Study 27329829 — intervention group
Group type: COMPARATOR
Intervention: Coronally advanced flap alone (CAF)
Number of subjects: 32
Study 24605986 — intervention group
Group type: EXPERIMENTAL
Intervention: Holiday food cues (Study 1)
Number of subjects: 262
Study 24605986 — intervention group
Group type: EXPERIMENTAL
Intervention: Holiday food cues (Study 2)
Number of subjects: 262
Study 24605986 — intervention group
Group type: COMPARATOR
Intervention: Neutral topic (Study 2)
Number of subjects: 262
Study 22907609 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg kg(‐1) bolus during induction, followed by 2 mg kg(‐1) h(‐1) intraoperative infusion and 1.3 mg kg(‐1) h(‐1) for 24 h postoperatively)
Number of subjects: 64
Study 22907609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 22907609 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 64
Study 20807345 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT)
Number of subjects: 148
Study 20807345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 16935035 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled furosemide (40 mg)
Number of subjects: 10
Study 16935035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 16388684 — intervention group
Group type: EXPERIMENTAL
Intervention: Center of pressure (COP) measures during reaching and leaning tasks
Number of subjects: 21
Study 16388684 — intervention group
Group type: EXPERIMENTAL
Intervention: Center of pressure (COP) measures during reaching expressed as a percentage of maximum COP displacement during leaning
Number of subjects: 21
Study 16388684 — intervention group
Group type: COMPARATOR
Intervention: Berg Balance Scale (BBS), Mini‐mental State Exam, Expanded Disability Status Scale (EDSS), Multiple Sclerosis Functional Composite (MSFC)
Number of subjects: 21
Study 12572373 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of methotrexate (MTX), sulfasalazine (SSZ) and Fengshi No. 1 (FS1)
Number of subjects: 60
Study 12572373 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) and sulfasalazine (SSZ) alone
Number of subjects: 60
Study 9440376 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine intake of 12 mg.kg‐1.d‐1
Number of subjects: 7
Study 9440376 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine intake of 28 mg.kg‐1.d‐1
Number of subjects: 7
Study 8595517 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1ra (100 mg bolus followed by 2.0 mg/kg/h i.v. for 72 h)
Number of subjects: 19
Study 8595517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 2235951 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisamid plus isoniazid, rifampicin, and streptomycin (or ethambutol)
Number of subjects: 145
Study 2235951 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid, rifampicin, and streptomycin (or ethambutol)
Number of subjects: 145
Study 227571 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CCNA, methotrexate, and adriamycin in epidermoid carcinoma
Number of subjects: 147
Study 227571 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CCNU, cyclophosphamide, and methotrexate in adenocarcinoma
Number of subjects: 147
Study 227571 — intervention group
Group type: COMPARATOR
Intervention: Combination of cyclophosphamide and adriamycin
Number of subjects: 147
Study 227571 — intervention group
Group type: COMPARATOR
Intervention: Combination of CCNU, procarbazine, and 5-fluorouracil
Number of subjects: 147
Study 227571 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective responders and stable responders
Number of subjects: 147
Study 227571 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete remission in epidermoid carcinoma
Number of subjects: 147
Study 227571 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients ≥50% bedridden
Number of subjects: 147
Study 30465868 — intervention group
Group type: EXPERIMENTAL
Intervention: Texture analysis on T2w FLAIR MRI
Number of subjects: 41
Study 30465868 — intervention group
Group type: EXPERIMENTAL
Intervention: Texture analysis on ADC MRI
Number of subjects: 41
Study 30465868 — intervention group
Group type: EXPERIMENTAL
Intervention: Texture analysis on T1w MRI
Number of subjects: 41
Study 30465868 — intervention group
Group type: EXPERIMENTAL
Intervention: Texture analysis on T1w + Gd MRI
Number of subjects: 41
Study 30465868 — intervention group
Group type: EXPERIMENTAL
Intervention: MDF values for discrimination
Number of subjects: 41
Study 30465868 — intervention group
Group type: COMPARATOR
Intervention: Histogram parameters
Number of subjects: 41
Study 27461168 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorghum bicolor extract (500 mg/d) + folic acid (5 mg/d) + iron (200 mg three times daily)
Number of subjects: 66
Study 27461168 — intervention group
Group type: COMPARATOR
Intervention: Routine hematinics (folic acid 5 mg/d and iron 200 mg three times daily)
Number of subjects: 66
Study 25068560 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus OMT (OMT)
Number of subjects: 400
Study 25068560 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus placebo ultrasound treatment (PUT)
Number of subjects: 400
Study 25068560 — intervention group
Group type: COMPARATOR
Intervention: Usual care only (UCO)
Number of subjects: 400
Study 25068560 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcome of meconium-stained amniotic fluid
Number of subjects: 400
Study 23426033 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (600 mg/d)
Number of subjects: 350
Study 23426033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 21768541 — intervention group
Group type: COMPARATOR
Intervention: Soy protein supplementation (40 g/d for 8 weeks)
Number of subjects: 352
Study 21768541 — intervention group
Group type: COMPARATOR
Intervention: Milk protein supplementation (40 g/d for 8 weeks)
Number of subjects: 352
Study 21768541 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation (control)
Number of subjects: 352
Study 21768541 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein vs Milk protein
Number of subjects: 352
Study 19961750 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-screw implants
Number of subjects: 42
Study 19961750 — intervention group
Group type: COMPARATOR
Intervention: Transpalatal arch (TPA)
Number of subjects: 42
Study 17027360 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test
Number of subjects: 38
Study 14605283 — intervention group
Group type: EXPERIMENTAL
Intervention: Super-flux dialysis
Number of subjects: 45
Study 14605283 — intervention group
Group type: COMPARATOR
Intervention: High-flux dialysis
Number of subjects: 45
Study 14605283 — intervention group
Group type: COMPARATOR
Intervention: Low-flux dialysis
Number of subjects: 45
Study 10741813 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (5 ml of 0.25% bupivacaine at each incisional area, total of 20 ml)
Number of subjects: 28
Study 10741813 — intervention group
Group type: COMPARATOR
Intervention: Control (physiologic saline solution, total of 20 ml)
Number of subjects: 28
Study 10741813 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 28
Study 10741813 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 28
Study 9373821 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunistic health screening tool
Number of subjects: 0
Study 9373821 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 1586367 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural therapy (exposure in vivo and response prevention)
Number of subjects: 6
Study 1586367 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 6
Study 1586367 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural therapy followed by cognitive therapy
Number of subjects: 6
Study 1586367 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy followed by behavioural therapy
Number of subjects: 6
Study 3515932 — intervention group
Group type: EXPERIMENTAL
Intervention: Moricizine (Ethmozine)
Number of subjects: 17
Study 31292531 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 1150
Study 31292531 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1150
Study 30439322 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuebijing injection
Number of subjects: 189
Study 30439322 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 189
Study 27213491 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Number of subjects: 136
Study 27213491 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure
Number of subjects: 136
Study 27213491 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher consistency in session attendance
Number of subjects: 136
Study 27213491 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer time interval between Sessions 4 and 5
Number of subjects: 136
Study 24338242 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnographic monitoring
Number of subjects: 533
Study 24338242 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring
Number of subjects: 533
Study 24338242 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesiologist-administered sedation
Number of subjects: 533
Study 24338242 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-administered propofol sedation (NAPS) or endoscopist-directed sedation (EDS)
Number of subjects: 533
Study 23240152 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (melaxen, 1.5 mg, 2 weeks)
Number of subjects: 0
Study 23240152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20479445 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic splinting for nightly wear to obtain a low-load, prolonged-duration stretch with dynamic tension
Number of subjects: 60
Study 20479445 — intervention group
Group type: COMPARATOR
Intervention: Control group (received nonsteroidal anti-inflammatory drugs, orthoses, and corticosteroid injections if needed)
Number of subjects: 60
Study 18690305 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg bid)
Number of subjects: 32
Study 18690305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 15230045 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine 60 mg/day for 4 weeks
Number of subjects: 47
Study 15230045 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 47
Study 11382726 — intervention group
Group type: EXPERIMENTAL
Intervention: GP IIb/IIIa antagonist therapy with >/=95% platelet inhibition at 10 minutes after therapy initiation
Number of subjects: 500
Study 11382726 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet function inhibition <70% at 8 hours after therapy initiation
Number of subjects: 500
Study 11382726 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet function inhibition >/=95% at 10 minutes after therapy initiation
Number of subjects: 500
Study 9404700 — intervention group
Group type: EXPERIMENTAL
Intervention: High STn expression (defined as >25% cells immunoreactive)
Number of subjects: 207
Study 9404700 — intervention group
Group type: EXPERIMENTAL
Intervention: High STn expression
Number of subjects: 207
Study 9404700 — intervention group
Group type: COMPARATOR
Intervention: Low STn expression
Number of subjects: 207
Study 8102894 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (Claforan) 2 g intravenously at induction and 3 and 9 hours later (n = 280)
Number of subjects: 567
Study 8102894 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime 2 g plus metronidazole (Flagyl) 1.5 g intravenously at induction (n = 287)
Number of subjects: 567
Study 3111953 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin III (AT III) concentrate
Number of subjects: 39
Study 3111953 — intervention group
Group type: COMPARATOR
Intervention: FOY (injectable synthetic protease inhibitor)
Number of subjects: 39
Study 29884217 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified care based on STarT Back Tool classification
Number of subjects: 0
Study 29884217 — intervention group
Group type: COMPARATOR
Intervention: Current practice (physiotherapists blinded to STarT score)
Number of subjects: 0
Study 29884217 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified care
Number of subjects: 0
Study 29884217 — intervention group
Group type: COMPARATOR
Intervention: Current practice
Number of subjects: 0
Study 26941098 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI using ZP-bound sperm
Number of subjects: 84
Study 26941098 — intervention group
Group type: COMPARATOR
Intervention: Standard ICSI
Number of subjects: 84
Study 25239512 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-trampoline (MT)
Number of subjects: 74
Study 25239512 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic gymnastics (AG)
Number of subjects: 74
Study 25239512 — intervention group
Group type: EXPERIMENTAL
Intervention: General floor gymnastics (GG)
Number of subjects: 74
Study 23644995 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting lower arterial oxygen saturations (85% to 89%)
Number of subjects: 1201
Study 23644995 — intervention group
Group type: COMPARATOR
Intervention: Targeting higher arterial oxygen saturations (91% to 95%)
Number of subjects: 1201
Study 20821817 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (AG)
Number of subjects: 35
Study 20821817 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture (SG)
Number of subjects: 35
Study 18467725 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial adjuvant treatment with fluorouracil (FU)-based therapy
Number of subjects: 17381
Study 18467725 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 17381
Study 18467725 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial stage II disease
Number of subjects: 17381
Study 18467725 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients entered more recently onto trials (1986 to 1999)
Number of subjects: 17381
Study 16642886 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 68
Study 16642886 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 68
Study 16642886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 12556006 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 mcg twice daily
Number of subjects: 456
Study 12556006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 456
Study 10987161 — intervention group
Group type: EXPERIMENTAL
Intervention: Unna semirigid dressings (SRD)
Number of subjects: 21
Study 10987161 — intervention group
Group type: COMPARATOR
Intervention: Elastic bandage soft dressings (ED)
Number of subjects: 21
Study 8978020 — intervention group
Group type: EXPERIMENTAL
Intervention: Live varicella zoster virus (VZV) vaccine
Number of subjects: 0
Study 8978020 — intervention group
Group type: COMPARATOR
Intervention: Killed varicella zoster virus (VZV) vaccine
Number of subjects: 0
Study 1462639 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcrystalline collagen powder (CL)
Number of subjects: 62
Study 1462639 — intervention group
Group type: COMPARATOR
Intervention: Fibrin glue (FG)
Number of subjects: 62
Study 6152344 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin-octapeptide (CCK-8) 10 micrograms weekly intravenous injections
Number of subjects: 18
Study 6152344 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 18
Study 30719442 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplatz group (AG)
Number of subjects: 66